What it is
PT-141, or bremelanotide, is a synthetic cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH). It is a melanocortin receptor agonist, acting mainly at MC4R (and also MC3R and MC1R). Its relevant action for sexual function is central: it activates melanocortin pathways in the hypothalamus and limbic regions that sit upstream of sexual desire and arousal, rather than acting on blood vessels the way PDE5 inhibitors do.
It is a regulated medicine. Bremelanotide was approved in 2019 (marketed as Vyleesi) for premenopausal women with acquired, generalised hypoactive sexual desire disorder. This is an adults-only sexual health context, and it should be treated as such.
What people use it for
The approved use is low sexual desire in premenopausal women. Off-label and in the research/community setting it is also explored for low libido and erectile difficulty in men, on the strength of its central mechanism. Because it works on desire centrally, people sometimes try it where vascular-only treatments fall short.
Typical dose range
The approved dose is 1.75 mg subcutaneously, taken as needed roughly 45 minutes before anticipated sexual activity, with a hard ceiling of no more than 8 doses per month and not more than one dose in any 24 hours. Community protocols sometimes use lower starting doses to gauge tolerance, because nausea is strongly dose-related. Going above the approved single dose increases side effects (especially nausea and blood pressure effects) without a clear benefit.
If reconstituting from powder, get the concentration and per-dose volume right rather than eyeballing it: Peptide Calculator - Reconstitution & Dosage | Buy Peptides UK
Half-life and frequency
The terminal half-life after a single subcutaneous dose is about 2.7 hours (roughly 1.9 to 4.0 hours). It is an as-needed, episodic medication, not a daily one. The label cap of 8 doses per month and a 24-hour minimum gap between doses exists partly to limit cumulative blood-pressure effects, so the dosing frequency rules are a safety feature, not red tape.
Reconstitution (typical)
The approved product comes as a ready-to-use autoinjector. Research powder is supplied lyophilised: let the vial reach room temperature, add bacteriostatic water slowly down the vial wall, and swirl gently to dissolve rather than shaking, which can denature the peptide. Choose your target concentration first so dosing is clean: Peptide Calculator - Reconstitution & Dosage | Buy Peptides UK
Storage
Lyophilised vial: store cold and dark, frozen at around -20 C for the long term. Reconstituted solution: refrigerate at 2 to 8 C, keep out of light, use within about 28 days, and do not freeze it (freeze-thaw cycles degrade peptides). The commercial autoinjector follows its own labelled storage instructions.
Common side effects
These are well documented from the controlled trials:
- Nausea. The standout effect, occurring in roughly 40 percent of people at the 1.75 mg dose. It is usually mild to moderate, tends to ease with repeated use, but a minority needed anti-nausea treatment. Worth anticipating, not ignoring.
- Flushing. Facial flushing commonly starts 15 to 45 minutes after dosing and can last 1 to 2 hours.
- Headache.
- Injection-site reactions.
- Transient blood pressure rise with a small heart-rate dip. Ambulatory monitoring showed a mean systolic increase around 2 mmHg with peaks up to roughly 6 mmHg, in the hours after dosing.
Because of the blood-pressure effect, bremelanotide is contraindicated in uncontrolled hypertension and known cardiovascular disease. It is not for evening/bedtime use in a way that would leave the BP rise unmonitored, and it is not appropriate for people with significant heart risk. A related, mostly cosmetic effect from melanocortin activation is darkening of the skin or gums with repeated use, more so in people with darker skin or who dose frequently.
Stacking and co-solubility
In community use PT-141 is sometimes discussed alongside other agents for sexual function, but combining it with anything that also moves blood pressure (including, in the worst case, other vasoactive substances or recreational drugs) stacks cardiovascular risk and is the main thing to avoid. There is no controlled human evidence supporting a particular stack. If combined with another peptide at all, that is done from separate vials, not co-mixed. Keep the blood-pressure interaction front of mind.
Evidence grade (human RCT / small human / animal-only / anecdote)
Human RCT for the approved use. The female HSDD indication is backed by large randomised, double-blind, placebo-controlled trials, which is why it reached approval. The effect size is real but modest, and the trials were in premenopausal women specifically.
Use in men, and use for erectile difficulty, is supported by earlier and smaller human work plus mechanism, but is weaker and off-label. General “libido booster” use sits closer to anecdote. The pharmacology (half-life, BP effect, nausea rate) is well characterised from regulatory data.
Honest unknowns
- Long-term safety of repeated use beyond the trial windows, including cumulative cardiovascular effect, is not fully characterised.
- The male efficacy data is thinner than the female data; how well it works for men is less certain than the marketing suggests.
- Interaction risk with other blood-pressure-active substances is under-studied and is the most plausible route to a serious problem.
- Non-prescription supply is unregulated, so dose accuracy, purity and sterility vary between sources.
Research use only. Not medical advice. 18+.